Literature DB >> 25255179

Efficacy and safety of a modified-live cyprinid herpesvirus 3 vaccine in koi (Cyprinus carpio koi) for prevention of koi herpesvirus disease.

E P Scott Weber1, Kirsten V Malm, Susan C Yun, Lori A Campbell, Philip H Kass, Gary D Marty, Kira Salonius, Arnon Dishon.   

Abstract

OBJECTIVE: To investigate safety and efficacy of a cyprinid herpesvirus type 3 (CyHV3) modified-live virus vaccine for the prevention of koi herpesvirus disease (KHVd). ANIMALS: 420 healthy koi (Cyprinus carpio koi). PROCEDURES: Fish were vaccinated with a 1× dose or 10× overdose of CyHV3 modified-live virus vaccine or a placebo through bath exposure in tanks at 22°C. Horizontal transmission of vaccine virus was evaluated by commingling unvaccinated and vaccinated fish. Efficacy was evaluated by challenge exposure of vaccinated and naïve fish to a wild-type virus. Fish that died were submitted for quantitative PCR assay for CyHV3 and histologic evaluation.
RESULTS: The CyHV3 vaccine was safe and efficacious, even at a 10× overdose. Vaccine-associated mortality rate was inversely associated with body weight, with a cumulative mortality rate of 9.4% (18/192) in fish weighing ≤ 87 g and no deaths in fish weighing > 87 g (0/48). Horizontal transfer of vaccine virus from vaccinates to naïve fish was negligible. For efficacy, the vaccine provided a significant reduction in mortality rate after challenge exposure to a wild-type virus, with a prevented fraction of 0.83 versus the placebo control fish. CONCLUSIONS AND CLINICAL RELEVANCE: KHVd is highly contagious and commonly leads to deaths in 80% to 100% of exposed fish, representing a major threat to koi and common carp populations throughout the world. The CyHV3 modified-live virus vaccine had a favorable safety profile and was an effective vaccine for the control of KHVd in koi weighing > 87 g.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25255179     DOI: 10.2460/ajvr.75.10.899

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Rational development of an attenuated recombinant cyprinid herpesvirus 3 vaccine using prokaryotic mutagenesis and in vivo bioluminescent imaging.

Authors:  Maxime Boutier; Maygane Ronsmans; Ping Ouyang; Guillaume Fournier; Anca Reschner; Krzysztof Rakus; Gavin S Wilkie; Frédéric Farnir; Calixte Bayrou; François Lieffrig; Hong Li; Daniel Desmecht; Andrew J Davison; Alain Vanderplasschen
Journal:  PLoS Pathog       Date:  2015-02-20       Impact factor: 6.823

2.  Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion.

Authors:  Sandro Klafack; Lars Schröder; Yeonhwa Jin; Matthias Lenk; Pei-Yu Lee; Walter Fuchs; Jean-Christophe Avarre; Sven M Bergmann
Journal:  NPJ Vaccines       Date:  2022-09-06       Impact factor: 9.399

3.  Genomic and biologic comparisons of cyprinid herpesvirus 3 strains.

Authors:  Yuan Gao; Nicolás M Suárez; Gavin S Wilkie; Chuanfu Dong; Sven Bergmann; Pei-Yu Alison Lee; Andrew J Davison; Alain F C Vanderplasschen; Maxime Boutier
Journal:  Vet Res       Date:  2018-05-02       Impact factor: 3.683

4.  Diagnostic validation of a rapid and field-applicable PCR-lateral flow test system for point-of-care detection of cyprinid herpesvirus 3 (CyHV-3).

Authors:  Finn N Loose; André Breitbach; Ivo Bertalan; Dana Rüster; Uwe Truyen; Stephanie Speck
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

5.  Pharmacokinetic and Efficacy Study of Acyclovir Against Cyprinid Herpesvirus 3 in Cyprinus carpio.

Authors:  Eva Marie Quijano Cardé; Zeinab Yazdi; Susan Yun; Ruixue Hu; Heather Knych; Denise M Imai; Esteban Soto
Journal:  Front Vet Sci       Date:  2020-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.